The Oncology Journal Club Episode 40: ASCO 2021 GI Special
In today’s special ASCO 2021 GI episode Eva Segelov and Hans Prenen chat to Pam Kunz and Marc Peeters. Addressing both upper and lower GI, both interviews cover practice changing developments and controversial trials.
We hope you enjoy listening… drop us a line on Twitter with any comments.
This Week’s Papers:
Marc Peeters Interview:
- Shiu, K-K., et al. KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer. J Clin Oncol 39, 2021 (suppl 3; abstr 6). DOI: 10.1200/JCO.2021.39.3_suppl.6. Access online here.
- Kopetz, S., et al. Overall survival (OS) with encorafenib (enco) + cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC). J Clin Oncol 39, 2021 (suppl 15; abstr 3583). DOI: 10.1200/JCO.2021.39.15_suppl.3583. Access online here.
- Stintzing, S., et al. Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116).J Clin Oncol 39, 2021 (suppl 15; abstr 3502). DOI: 10.1200/JCO.2021.39.15_suppl.3502. Access online here.
- Yoshino, T., et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01). J Clin Oncol 39, 2021 (suppl 15; abstr 3505). DOI: 10.1200/JCO.2021.39.15_suppl.3505. Access online here.
- Pratap Singh Raghav, K., et al. Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02). J Clin Oncol 39, 2021 (suppl 15; abstr TPS3620). DOI: 10.1200/JCO.2021.39.15_suppl.TPS3620. Access online here.
- Mariani, S., et al. Liquid biopsy-driven anti-EGFR rechallenge in patients with metastatic colorectal cancer. J Clin Oncol 39, 2021 (suppl 15; abstr 3577). DOI: 10.1200/JCO.2021.39.15_suppl.3577. Access online here.
- Adams, R., et al. Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized FOCUS4-N trial. J Clin Oncol 39, 2021 (suppl 15; abstr 3504). DOI: 10.1200/JCO.2021.39.15_suppl.3504. Access online here.
Pam Kunz Interview:
- Chau, I., et al. Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study. J Clin Oncol 39, 2021 (suppl 15; abstr LBA4001). DOI:
- Moehler, M.H., et al. First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649. J Clin Oncol 39, 2021 (suppl 15; abstr 4002). DOI: 10.1200/JCO.2021.39.15_suppl.4002. Access online here.
- Janjigian, Y.Y., et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study.J Clin Oncol 39, 2021 (suppl 15; abstr 4013). DOI: 10.1200/JCO.2021.39.15_suppl.4013. Access online here.
- Guo, W., et al. Phase III trial comparing XELOX regimen (oxaliplatin plus capecitabine) versus EOX regimen (epirubicin, oxaliplatin and capecitabine) as first-line treatment for advanced gastric cancer: EXELOX trial. J Clin Oncol 39, 2021 (suppl 15; abstr 4014). DOI: 10.1200/JCO.2021.39.15_suppl.4014. Access online here.
- Kelly, RJ., et al. Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577. J Clin Oncol 39, 2021 (suppl 15; abstr 4003). DOI: 10.1200/JCO.2021.39.15_suppl.4003. Access online here.
- Ozaka, M., et al. Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407). J Clin Oncol 39, 2021 (suppl 15; abstr 4017). DOI: 10.1200/JCO.2021.39.15_suppl.4017. Access online here.
- Schram, A.M., et al. Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions. J Clin Oncol 39, 2021 (suppl 15; abstr 3003). DOI: 10.1200/JCO.2021.39.15_suppl.3003. Access online here.
- Subbiah, V., et al. Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors: Update from the ARROW trial. J Clin Oncol 39, 2021 (suppl 15; abstr 3079). DOI: 10.1200/JCO.2021.39.15_suppl.3079. Access online here.
- Yoo,C., et al. Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): Multicenter comparative randomized phase 2b study (NIFTY). J Clin Oncol 39, 2021 (suppl 15; abstr 4006). DOI: 10.1200/JCO.2021.39.15_suppl.4006. Access online here.
- Catenacci, DVT., et al. FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC). J Clin Oncol 39, 2021 (suppl 15; abstr 4010) DOI: 10.1200/JCO.2021.39.15_suppl.4010. Access online here.
- Kunz, PL. Looking Under the Surface: Exposing the Iceberg of Sexual Harassment. Session: Moving Toward Equity. Access online here.
This Week’s Team:
Professor Eva Segelov
Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.
Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.
You can find Eva on Twitter here: @profevasegelov
Professor Hans Prenen
Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings. His interests are clinical trials and translational research with a focus on digestive oncology.
You can find Hans on Twitter here: @HPrenen
Professor Marc Peeters
Marc Peeters is Professor of oncology at the Antwerp University, Belgium. He is head of the oncology department at the Antwerp University Hospital and coordinator of the Multidisciplinary Oncology Center Antwerp. He is also chairman of the College of Oncology. Previously, he was Coordinator of the Digestive Oncology Unit at the University Hospital in Ghent, Belgium. He completed his medical studies at the Catholic University in Leuven, Belgium. He underwent additional training in Oncology and Digestive Oncology at the UZ Gasthuisberg, the Institut Gustave Roussy in Villejuif, Paris, the University of Pennsylvania Hospital in Philadelphia, the Royal Marsden Hospital in London, and the Memorial Sloan-Kettering Cancer Center in New York.
Dr. Peeters is board member of the Flemish Society of Gastroenterology, chair of the Belgian Group of Digestive Oncology and member of the Belgian Society of Medical Oncology, the European Society of Medical Oncology, the American Society for Clinical Oncology and the gastrointestinal group of the European Organisation for Research and Treatment of Cancer. Within EORTC, he is co-chair of the metastatic colorectal task force.
His research interests have included the identification of molecular markers and therapy modulation in digestive tumors. He has been involved in many clinical studies on therapeutic agents for gastrointestinal tumors, published numerous articles in peer reviewed journals and was author of several chapters in oncology books.
Associate Professor Pamela Kunz
Dr. Kunz joins Yale from Stanford University School of Medicine where she was Director of the Stanford Neuroendocrine Tumor Program, Leader of the Endocrine Oncology Research Group, and Director of the Neuroendocrine Tumor Fellowship.
Beyond her record of accomplishment in GI Oncology, Dr. Kunz is an international leader in the clinical care of patients with neuroendocrine tumors (NETs) and is advancing the field through clinical trials and translational science that are defining the next generation of therapies for patients with this rare diagnosis.
Find Pam on Twitter here: @PamelaKunzMD
Rachael Babin is Editor-in-Chief of The Oncology Newsletter, Publisher of Oncology News Host of The Oncology Podcast and Producer of The Oncology Journal Club. For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.
With thanks to Eva Segelov, Craig Underhill, Hans Prenen, Kristi Milley and Graham Knowles.
Connect with us on Twitter @OncologyNewsAus